Day: September 21, 2021

CORRECTION: Rhythm Pharmaceuticals, Inc.

CORRECTION: Rhythm Pharmaceuticals, Inc.

BOSTON, Sept. 21, 2021 (GLOBE NEWSWIRE) — In a release issued on Wednesday, September 21 by Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), please note that the symbol ▼ was erroneously omitted from the headline. The corrected release follows: Rhythm Pharmaceuticals Announces Marketing Authorisation of ▼IMCIVREE® (setmelanotide) in Great Britain – IMCIVREE is indicated for treatment of obesity and control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children six years of age and above – – First-ever authorised treatment option in Great Britain (England, Scotland and Wales) for these rare genetic diseases of obesity – – IMCIVREE selected as ‘highly specialised technology’ and scheduled...

Continue reading

ISC Announces Dividend Increase

ISC Announces Dividend Increase

REGINA, Saskatchewan, Sept. 21, 2021 (GLOBE NEWSWIRE) — The Board of Directors (the “Board”) of Information Services Corporation (TSX:ISV) (“ISC” or the “Company”) today announced that it has approved an increase in the expected annual dividend of its Class A Limited Voting Share (“Class A Share”) from $0.80 to $0.92. The new annual dividend of $0.92 per Class A Share (declared and paid quarterly) is expected to commence when the Board next meets to consider its quarterly declaration for the third quarter of 2021 and is anticipated to remain at that amount until otherwise determined by the Board. The decision to increase the dividend reflects the strength of the Company’s current business and affirms the Company’s commitment to continue to reward shareholders as it grows. The declaration, amount and payment date of...

Continue reading

Isoray Reschedules Fourth Quarter and Fiscal Year End 2021 Financial Results Conference Call to September 22, 2021 Due to Conference Provider Technical Issues

Isoray Reschedules Fourth Quarter and Fiscal Year End 2021 Financial Results Conference Call to September 22, 2021 Due to Conference Provider Technical Issues

Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT RICHLAND, Wash., Sept. 21, 2021 (GLOBE NEWSWIRE) — Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, will host a rescheduled conference call to discuss its financial results for the fourth quarter and fiscal year ended June 30, 2021 on Wednesday, September 22, 2021, at 10:00 a.m. Eastern Time/7:00 a.m. Pacific. The rescheduled conference call was necessitated by the conference bridge provider’s technical failure. The Company has already issued a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2021. The press release was issued after the close of the U.S. stock markets on September 21, 2021. To...

Continue reading

Freddie Mac Prices Inaugural $170 Million Multifamily When-Issued K-Deal®, WI-K132

Freddie Mac Prices Inaugural $170 Million Multifamily When-Issued K-Deal®, WI-K132

MCLEAN, Va., Sept. 21, 2021 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) recently priced a new offering of Multifamily WI K-Deal Certificates (WI Certificates), which are initially backed by cash assets that will be used to purchase the A-M class of a to-be-issued reference K-Deal. Once the reference K-Deal class is issued and purchased by the WI trust, the WI Certificates will be indirectly backed by a pool of fixed-rate multifamily mortgages with predominantly 10-year terms. The company expects to issue approximately $170 million in WI Certificates (Series WI-K132), which are expected to settle on or about September 28, 2021. “Today we are pleased to announce the successful pricing of our inaugural WI K-Deal offering, WI-K132,” said Robert Koontz, senior vice president of Capital Markets for Freddie Mac Multifamily. “The WI K-Deal...

Continue reading

Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain

Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain

– IMCIVREE is indicated for treatment of obesity and control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children six years of age and above – – First-ever authorised treatment option in Great Britain (England, Scotland and Wales) for these rare genetic diseases of obesity – – IMCIVREE selected as ‘highly specialised technology’ and scheduled for review by National Institute for Health and Care Excellence (NICE) in December 2021 – BOSTON, Sept. 21, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that Great Britain’s...

Continue reading

Medexus Announces Expanded Availability of Trecondyv® (treosulfan) in Canada

Medexus Announces Expanded Availability of Trecondyv® (treosulfan) in Canada

TORONTO and CHICAGO, Sept. 21, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX: MDP) (OTCQX: MEDXF) announced today that it has initiated its first commercial shipment of Trecondyv® (treosulfan) in Canada, following the June 28th, 2021 Notice of Compliance by Health Canada, which had previously only been distributed under the Health Canada Special Access Program. Trecondyv® is a bifunctional alkylating agent developed for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation (“allo-HSCT”). Trecondyv® is now available for commercial sale in Canada for the treatment adult patients with Acute Myeloid Leukemia (“AML”) or Myelodysplastic Syndromes (“MDS”) who are at increased risk for standard conditioning therapies, as well as in pediatric...

Continue reading

Medolife Rx Clarifies April 13, 2021 Press Release

Medolife Rx Clarifies April 13, 2021 Press Release

BURBANK, Calif., Sept. 21, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Medolife Rx, Inc. (“Medolife” or the “Company”), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today two clarifications to its press release, dated April 13, 2021: 1.    The Company has conducted extensive preclinical studies on Escozine® as a therapeutic for both COVID-19 and multiple forms of cancer in the US and globally. 2.    The Company has conducted preclinical safety and efficacy research on Escozine® and is pursuing product registration and drug approval in various countries, including the United States, Dominican Republic and Mexico first through the following instruments: a.    The Pharmaceutical...

Continue reading

Oil-Dri Announces Indonesian Patent for Novel Mineral-Based Feed Additive Formulation

Oil-Dri Announces Indonesian Patent for Novel Mineral-Based Feed Additive Formulation

CHICAGO, Sept. 21, 2021 (GLOBE NEWSWIRE) — The unique technology that this mineral-based feed additive brings to the Indonesian animal protein industry has been recognized with Oil-Dri Corporation of America (NYSE: ODC) as the inventor. Oil-Dri, a leading manufacturer of sorbent minerals, announces today that the Indonesian Directorate General of Intellectual Property has issued Patent IDP-000071991, titled “Clay Product and Uses Thereof.” The patent protects the novel, mineral-based formulation used in Amlan’s existing natural feed additives, Varium® for poultry and NeoPrime® for swine, that provides animal protein producers with natural solutions to maintain intestinal health and optimize production efficiency. The products are sold and marketed in international markets by Amlan International, the animal health business...

Continue reading

Approval application for capacity resources will be withdrawn from Montana Public Service Commission

Approval application for capacity resources will be withdrawn from Montana Public Service Commission

Construction timeline for Laurel Generating Station, critical for reliable, affordable service for NorthWestern Energy’s Montana customers, will accelerate BUTTE, Mont., Sept. 21, 2021 (GLOBE NEWSWIRE) — NorthWestern Corporation d/b/a NorthWestern Energy (Nasdaq: NWE). A shortage of critical peak capacity electric resources is jeopardizing reliability in the Western United States. In Montana, exposure to volatile market prices is also an increasing risk to affordable service for NorthWestern Energy’s customers. NorthWestern Energy intends to withdraw our application for approval for new capacity resources with the Montana Public Service Commission to accelerate the construction of the 175-megawatt Laurel Generating Station natural gas plant. The upheaval in the construction market and, specifically, timely availability of critical...

Continue reading

GameSquare Esports Announces Results of Annual and Special Meeting

GameSquare Esports Announces Results of Annual and Special Meeting

TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) — GameSquare Esports Inc. (CSE: GSQ; FRA: 29Q1) (the “Company”), an international gaming and esports company, announces the results of its annual and special meeting of shareholders that was held on September 21, 2021 at 10:00 a.m. EST (the “Meeting”). The four matters voted on were (1) the election of directors; (2) the appointment of Kreston GTA LLP as the Company’s auditor for the coming year and authorization of the directors of the Company to fix such auditors’ remuneration; (3) the approval of the Company’s rolling stock plan; and (4) the approval of the Company’s restricted share unit compensation plan. All matters that were voted on at the Meeting were approved. The six individuals elected as directors are Tom Walker, Travis Goff, Justin Kenna, Paul LeBreux, Kevin Wright and Craig...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.